Researchers reported long-term remission of HIV-1 in a patient who received an allogeneic hematopoietic stem cell transplant from a sibling donor carrying the CCR5Δ32/Δ32 mutation. The result, detailed in Nature Microbiology, adds to evidence that targeting CCR5 can underpin durable viral control when combined with stem-cell replacement. While transplant-based cures remain limited by donor availability and procedure risk, the case strengthens mechanistic rationale for CCR5-focused strategies and supports continued interest in gene-edited or transplant-adjacent approaches that seek similar biology. The report also frames ongoing efforts to translate CCR5 disruption into less invasive modalities that can be scaled beyond rare transplant settings.